{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:59:35Z","timestamp":1761843575639,"version":"3.32.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,11,7]],"date-time":"2006-11-07T00:00:00Z","timestamp":1162857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,11,17]]},"DOI":"10.1007\/s00228-006-0210-3","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T10:20:23Z","timestamp":1162808423000},"page":"995-1001","source":"Crossref","is-referenced-by-count":26,"title":["Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia"],"prefix":"10.1007","volume":"62","author":[{"given":"Junji","family":"Saruwatari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Oniki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Marubayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kamataki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,11,7]]},"reference":[{"key":"210_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 369:23\u201337","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"210_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6\u201313","journal-title":"Pharmacogenomics J"},{"key":"210_CR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1389200033489523","volume":"4","author":"A Sharma","year":"2003","unstructured":"Sharma A, Hamelin BA (2003) Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird\u2019s eye view. Curr Drug Metab 4:105\u2013129","journal-title":"Curr Drug Metab"},{"key":"210_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","volume":"18","author":"T Shimizu","year":"2003","unstructured":"Shimizu T, Ochiai H, \u00c5sell F, Shimizu H, Saitoh R, Hama Y et al (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48\u201370","journal-title":"Drug Metab Pharmacokinet"},{"key":"210_CR5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00004714-200004000-00019","volume":"20","author":"WH Chou","year":"2000","unstructured":"Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M et al (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246\u2013251","journal-title":"J Clin Psychopharmacol"},{"key":"210_CR6","doi-asserted-by":"crossref","unstructured":"Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al (2004) CYP2D6 genotype: impact on adverse drug reactions and nonresponse during treatment with antidepressants\u2014a pilot study. Clin Pharmacol Ther 75:386\u2013393","DOI":"10.1016\/j.clpt.2003.12.015"},{"key":"210_CR7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mcp.2002.127111","volume":"72","author":"H Wuttke","year":"2002","unstructured":"Wuttke H, Rau T, Heide R, Bergmann K, B\u00f6hm M, Weil J et al (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse drug reactions. Clin Pharmacol Ther 72:429\u2013437","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00008571-200204000-00008","volume":"12","author":"I Schillevoort","year":"2002","unstructured":"Schillevoort I, de Boer A, van der Weide J, Steijns LSW, Roos RAC, Jansen PAF et al (2002) Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12:235\u2013240","journal-title":"Pharmacogenetics"},{"key":"210_CR9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","volume":"72","author":"J Brockm\u00f6ller","year":"2002","unstructured":"Brockm\u00f6ller J, Kirchheiner J, Schmider J, Walter S, Sachse C M\u00fcller-Oerlinghausen B et al (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438\u2013452","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0009-9236(95)90242-2","volume":"58","author":"ML Lai","year":"1995","unstructured":"Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD (1995) Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 58:264\u2013268","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(96)90133-2","volume":"60","author":"CY Tseng","year":"1996","unstructured":"Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD (1996) Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 60:177\u2013182","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008571-199710000-00013","volume":"7","author":"A Suzuki","year":"1997","unstructured":"Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y et al (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7:415\u2013418","journal-title":"Pharmacogenetics"},{"key":"210_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-005-0920-y","volume":"61","author":"F Fliegert","year":"2005","unstructured":"Fliegert F, Kurth B, G\u00f6hler K (2005) The effects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 61:257\u2013266","journal-title":"Eur J Clin Pharmacol"},{"key":"210_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00018-8","volume":"32","author":"O Ohmori","year":"1998","unstructured":"Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107\u2013113","journal-title":"Schizophr Res"},{"key":"210_CR15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ajmg.10602","volume":"114","author":"K Mihara","year":"2002","unstructured":"Mihara K, Kondo T, Higuchi H, Takahashi H, Yoshida K, Shimizu T et al (2002) Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors. Am J Med Genet 114:693\u2013695","journal-title":"Am J Med Genet"},{"key":"210_CR16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2125.2002.01578.x","volume":"53","author":"SU Yasuda","year":"2002","unstructured":"Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL (2002) The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 53:519\u2013525","journal-title":"Br J Clin Pharmacol"},{"key":"210_CR17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545","journal-title":"Sleep"},{"key":"210_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2869.2000.00177.x","volume":"9","author":"MW Johns","year":"2000","unstructured":"Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9:5\u201311","journal-title":"J Sleep Res"},{"key":"210_CR19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","volume":"5","author":"VM Steen","year":"1995","unstructured":"Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR et al (1995) Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215\u2013223","journal-title":"Pharmacogenetics"},{"key":"210_CR20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/clpt.1993.44","volume":"53","author":"SL Wang","year":"1993","unstructured":"Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410\u2013418","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.2000.00209.x","volume":"50","author":"T Kubota","year":"2000","unstructured":"Kubota T, Yamadura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31\u201334","journal-title":"Br J Clin Pharmacol"},{"key":"210_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","volume":"76","author":"I Zineh","year":"2004","unstructured":"Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536\u2013544","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clpt.2005.07.004","volume":"78","author":"R Fux","year":"2005","unstructured":"Fux R, M\u00f6rike K, Pr\u00f6hmer AM, Delabar U, Schwab M, Schaeffeler E et al (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378\u2013387","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","volume":"104","author":"J Kirchheiner","year":"2001","unstructured":"Kirchheiner J, Br\u00f8sen K, Dahl ML, Gram LF, Kasper S, Roots I et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173\u2013192","journal-title":"Acta Psychiatr Scand"},{"key":"210_CR25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01213011-200503000-00003","volume":"15","author":"NA Patsopoulos","year":"2005","unstructured":"Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP (2005) CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 15:151\u2013158","journal-title":"Pharmacogenet Genomics"},{"key":"210_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1081-1206(10)61946-1","volume":"89","author":"H Milgrom","year":"2002","unstructured":"Milgrom H, Bender B, Wamboldt F (2002) Of injuries and antihistamines and dosing. Ann Allergy Asthma Immunol 89:221\u2013223","journal-title":"Ann Allergy Asthma Immunol"},{"key":"210_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2005.04.006","volume":"78","author":"LS Lee","year":"2005","unstructured":"Lee LS, Nafziger AN, Bertino JS Jr (2005) Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 78:1\u20136","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00228-004-0757-9","volume":"60","author":"EF Vuurman","year":"2004","unstructured":"Vuurman EF, Rikken GH, Muntjewerff ND, de Halleux, Ramaekers JG (2004) Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 60:307\u2013313","journal-title":"Eur J Clin Pharmacol"},{"key":"210_CR29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1081-1206(10)61950-3","volume":"89","author":"WD Finkle","year":"2002","unstructured":"Finkle WD, Adams JL, Greenland S, Melmon KL (2002) Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 89:244\u2013250","journal-title":"Ann Allergy Asthma Immunol"},{"key":"210_CR30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00228-001-0399-0","volume":"57","author":"N He","year":"2002","unstructured":"He N, Zhang WQ, Shockley D, Edeki T (2002) Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 57:847\u2013851","journal-title":"Eur J Clin Pharmacol"},{"key":"210_CR31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3565(24)37273-8","volume":"284","author":"K Nakamura","year":"1998","unstructured":"Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N et al (1998) Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 284:437\u2013442","journal-title":"J Pharmacol Exp Ther"},{"key":"210_CR32","first-page":"536","volume":"26","author":"BA Hamelin","year":"1998","unstructured":"Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J (1998) In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 26:536\u2013539","journal-title":"Drug Metab Dispos"},{"key":"210_CR33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1067\/mcp.2000.106464","volume":"67","author":"BA Hamelin","year":"2000","unstructured":"Hamelin BA, Bouayad A, M\u00e9thot J, Jobin J, Desgagn\u00e9s P, Poirier P et al (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466\u2013477","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1989.136","volume":"46","author":"T Walle","year":"1989","unstructured":"Walle T, Walle UK, Cowart TD, Conradi EC (1989) Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46:257\u2013263","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00008571-200007000-00006","volume":"10","author":"L Labbe","year":"2000","unstructured":"Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J et al (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425\u2013438","journal-title":"Pharmacogenetics"},{"key":"210_CR36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clpt.2004.08.021","volume":"76","author":"Z Bebia","year":"2004","unstructured":"Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A et al (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618\u2013627","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","volume":"42","author":"JB Schwartz","year":"2003","unstructured":"Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107\u2013121","journal-title":"Clin Pharmacokinet"},{"key":"210_CR38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","volume":"16","author":"JL Montastruc","year":"2002","unstructured":"Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A (2002)Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fund Clin Pharmacol 16:343\u2013346","journal-title":"Fund Clin Pharmacol"},{"key":"210_CR39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","volume":"14","author":"GD Anderson","year":"2005","unstructured":"Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 14:19\u201329","journal-title":"J Womens Health"},{"key":"210_CR40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/026988110201600104","volume":"16","author":"A Vermeeren","year":"2002","unstructured":"Vermeeren A, Ramaekers JG, O\u2019Hanlon JF (2002) Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 16:57\u201364","journal-title":"J Psychopharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0210-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0210-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T21:42:42Z","timestamp":1736631762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0210-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,7]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,11,17]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0210-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2006,11,7]]}}}